Friday, March 6, 2009

International Stem Cell Corporation Hosts Webinar, "Stem Cells 102: Beyond Embryonic Stem Cell Research," Thursday, March 12, 2009, From 1:00pm-2:00pm

Free Educational Webinar for Journalists, Shareholders, and Investment Professionals

International Stem Cell Corporation (OTCBB:ISCO) (, the first company to perfect a method of creating human "parthenogenetic" stem cells from unfertilized eggs, will host a webinar titled "Stem Cells 102: Beyond Embryonic Stem Cell Research," Thursday, March 12, 2009, from 1:00pm-2:00pm EDT. This free educational webinar is for journalists, shareholders, and investment professionals interested in learning about new emerging technology in the stem cell research arena.
Please note that space is limited. Interested parties are invited to make a reservation to participate in the webinar by using the following link:

Covered in the webinar:
What is a pluripotent stem cell?
What are the implications of the FDA's recent approval of Geron clinical trials?
What is parthenogenesis and how does this process solve certain ethical and immune rejection issues that have long shadowed stem cell research?
How close are we to treating diseases with stem cells?

The company is hosting this event due to renewed interest in the sector given the FDA's recent approval of human trials of embryonic stem cells and President Obama's commitment to lifting federal research bans.

For more news and information on International Stem Cell Corporation please visit where you can find the CEO's video, a fact sheet on the company, investor presentations, and more.

International Stem Cell Corporation is a California biotechnology company focused on developing therapeutic and research products. ISCO's technology, Parthenogenesis, results in the creation of pluripotent human stem cell lines from unfertilized human eggs. ISCO scientists have created the first Parthenogenetic homozygous stem cell line (phSC-Hhom-4) that can be a source of therapeutic cells that will minimize immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. These advancements offer the potential to create the first true "Stem Cell Bank" and address ethical issues by eliminating the need to use or destroy fertilized embryos. ISCO also produces and markets specialized cells and growth media worldwide for therapeutic research through its subsidiary Lifeline Cell Technology. For more information, visit the ISCO website at:
To subscribe to receive ongoing corporate communications please click on the following link: .

Statements pertaining to anticipated future financial and/or operating results, future growth in research, technology, clinical development and potential joint venture and other opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.
Key Words: Stem Cells, Biotechnology, Parthenogenesis

International Stem Cell Corporation

Kenneth C. Aldrich, Chairman, CEO 760-940-6383

Jeffrey Janus, President 760-940-6383 or

The Investor Relations Group 212-825-3210

Investor Relations:Adam S. or Media Relations:Laura

No comments:

Post a Comment